Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Gastrointestinal 2Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Solid Tumors 1

Interventions

pembrolizumab 14Injections 13Pemetrexed 9Specimen Handling 8Carboplatin 8tislelizumab 7Interviews as Topic 7Cisplatin 7fludarabine 5atezolizumab 5Educational Status 5Cyclophosphamide 5Standard of Care 4Practice Guidelines as Topic 4Methods 4Fluorouracil 4Early Intervention, Educational 4Capecitabine 4Biopsy 4Bevacizumab 4Trastuzumab 3Platinum 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Magnetic Resonance Spectroscopy 3Docetaxel 3Cetuximab 31,2-diaminocyclohexaneplatinum II citrate 3toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
spartalizumab × Other solid neoplasm × 30 days × Clear all
NCT05155332 2026-05-20

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Boehringer Ingelheim

Phase 1 Suspended
190 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡